

SUPPLEMENTARY DATA

Supplementary Table 1. Insulin Access and Affordability Working Group Members

Chair: William T. Cefalu, MD, Chief Scientific, Medical and Mission Officer			
Board Members			
<u>Name</u>	Title	Affiliation	Location
Alvin C. Powers, MD	ADA President, Medicine & Science, 2017	Joe C. Davis Chair in Biomedical Science; Professor of Medicine in Molecular Physiology and Biophysics; Director of the Vanderbilt Diabetes Center; and Director of the Division of Diabetes and Endocrinology, Vanderbilt University School of Medicine	Nashville, TN
Alan L. Yatvin, JD	Member, ADA Board of Directors, 2015 - 2017	Popper & Yatvin	Philadelphia, PA
Expert Members			
Daniel E. Dawes, JD	Associate Professor	H. Wayne Huizenga College of Business and Entrepreneurship, Nova Southeastern University	Fort Lauderdale, FL
Gina Gavlak, RN, BSN	President & CEO	North Coast Health	Lakewood, OH
Dana P. Goldman, PhD	Leonard D. Schaeffer Chair and Director	USC Schaeffer Center for Health Policy & Economics	Los Angeles, CA
William H. Herman, MD, MPH	Professor of Internal Medicine and Epidemiology	University of Michigan	Ann Arbor, MI
Simeon I. Taylor, MD, PhD	Professor of Medicine, and Director of the Mid-Atlantic Nutrition Obesity Research Center	University of Maryland School of Medicine	Baltimore, MD
Karen Van Nuys, PhD	Executive Director, Value in Life Sciences Innovation Project	USC Schaeffer Center for Health Policy & Economics	Los Angeles, CA
ADA Staff			
Michelle Kirkwood	Vice President, Strategic Communications & Public Relations	ADA	Arlington, VA
Krista Maier, JD	Vice President, Public Policy & Strategic Alliances	ADA	Arlington, VA
LaShawn McIver, MD, MPH	Senior Vice President, Government Affairs &	ADA	Arlington, VA

SUPPLEMENTARY DATA

	Advocacy		
Mary Merkin	Senior Manager, Scientific, Medical & Mission	ADA	Arlington, VA
Meghan Riley	Vice President, Federal Government Affairs	ADA	Arlington, VA

SUPPLEMENTARY DATA

Supplementary Table 2. Category and number of Stakeholders that interacted with Working Group

Pharmaceutical Companies: N = 6
Pharmacy Benefit Managers: N = 2
Pharmacies or their representatives: N = 5
Health Plans/Systems: N = 5
Distributors: N = 1
Other: ACCIS Study Investigators; health service startup
Patient Group: Convened individuals with diabetes

Supplementary Table 3. Sample Questions addressed to Stakeholders

What are the main issues and concerns you have with the current drug pricing system throughout the supply chain? What is the biggest challenge your company or organization faces in the insulin supply chain?
What are the most important factors driving price increases and growing costs for insulin?
What proposed changes to the system would mitigate your company or organization's concerns and help lower the cost of insulin for patients?
How can stakeholders work together to find a long-term, sustainable solution to make insulin affordable for individuals with diabetes?
How can the ADA help find a long-term solution to make insulin affordable for individuals with diabetes?
Manufacturers: Can you provide information on how pricing for your new and existing insulins is established? What criteria are used to arrive at a suggested list price?
PBMs: What factors influence placement for the new and existing insulins on a particular formulary?
PBMs: Can you comment on factors that affect the list price from the manufacturers? What factors are involved in establishing, suggesting, or negotiating a rebate? What factors determine other administrative fees?
PBMs: How are rebates passed on to consumers either directly or indirectly through insurers/employers?
PBMs: What is your role in keeping down prices for uninsured/underinsured/high deductible/donut hole consumers?
Health Plans: How does your company determine the formulary, tiering, and cost-sharing for insulins?
Pharmacists: How do pharmacists interact with manufacturers, PBMs, and pharmacies?
Individuals with Diabetes: What type of health coverage do you have?
Individuals with Diabetes: What are your out-of-pocket costs for insulin? What impact has this had on you? For example, have you cut back on other expenses? Has it impacted your insulin dosing?
Individuals with Diabetes: Are you using any services to help mitigate the cost of insulin?